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The impact of risk-related parameters has not been deﬁned in transplantation settings. We wondered
whether the currently recognized predictors could be used to categorize acute myeloid leukemia (AML)
patients who underwent transplantation during remission into risk groups. We analyzed the data of 255
consecutive patients (median age, 26) with AML in their ﬁrst or second remission (CR1 or CR2) after hap-
loidentical hematopoietic stem cell transplantation (HSCT). Three parameters were found to be predictive of
outcome: response after induction therapy, white blood cell count at diagnosis, and cytogenetics. These three
factors were combined to yield two risk groups. The 2-year cumulative incidences of relapse for patients at
low and high risk were 8% and 36% (P ¼ .001), respectively. The 3-year probabilities of leukemia-free survival
for these two groups were 80% and 52% (P ¼ .001), respectively. Multivariate analysis for relapse and for
leukemia-free survival showed that not achieving CR after two courses of therapy was the strongest inde-
pendent prognostic factor (P ¼ .001 and P ¼ .028, respectively). In addition, in a subgroup of patients with
quantiﬁcation of minimal residual disease at the time of HSCT, positive minimal residual disease at this time
point was correlated with a poor outcome. Our results suggest that the pretransplantation risk factors
inﬂuence posttransplantation outcomes of patients with AML in CR after haploidentical HSCT and might be
applicable to assist with risk-directed posttransplantation therapy.
 2013 American Society for Blood and Marrow Transplantation.INTRODUCTION management to improve the outcomes of advanced-stage
Acute myeloid leukemia (AML) is a heterogeneous
disorder characterized by many prognostic parameters. In
patients undergoing chemotherapy, the morphology, cyto-
genetics, immunophenotype, and white blood cell (WBC)
count at diagnosis and response after induction therapy have
been proven to affect outcomes [1,2]. Studies have shown
that, compared with chemotherapy alone, a signiﬁcant
beneﬁt can be achieved with allogeneic hematopoietic stem
cell transplantation (allo-HSCT) in AML patients in their
ﬁrst complete remission (CR1) who have intermediate- or
poor-risk cytogenetics [3]. Allo-HSCT is currently considered
the treatment of choice for AML patients in their ﬁrst
complete remission (CR1) without favorable cytogenetics.
For patients with favorable cytogenetics, because of the
high incidence of transplantation-related mortality (TRM)
reported, allo-HSCT is not currently recommended as the
preferred choice.
We wondered whether AML patients who underwent
transplantation during CR have different prognoses after
uniformly performed allo-HSCT. It is widely known that the
outcomes are very poor for patients with advanced-stage
AML, even after allo-HSCT [4-6]. Many researchers,
including ourselves, have focused on posttransplantationdgments on page 289.
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12.10.002leukemia patients. Recently, we reported that prophylactic
use of donor lymphocyte infusion (DLI) can increase the
survival of patients with advanced-stage acute leukemia [7].
We were interested in risk factor evaluation of patients
undergoing transplantation during CR and the identiﬁcation
of patients with high-risk features whose outcomesmight be
as poor as those of patients with advanced-stage AML.
Therefore, more robust posttransplantation therapies might
be applied in these patients with high-risk features, even
after transplantation during CR and might further improve
the overall outcomes of patients with AML in CR after allo-
HSCT.
For AML patients undergoing HSCT during CR, cytoge-
netics is the most often investigated predictor [8-11]. To our
knowledge, there has been only one study that evaluated the
role of risk factors, including cytogenetics, response after
induction therapy, and French-American-British (FAB) type,
on transplantation outcomes in matched-sibling HSCT
settings [10]. We wondered whether the currently recog-
nized predictors could be used to categorize into risk groups
AML patients who underwent transplantation during
remission and whether these predictors would be applicable
in HSCT patients. The goal of the current study was to
attempt to answer these two questions by analyzing the data
on haploidentical HSCT, which is a uniformly performed
treatment modality.
METHODS
Patient Eligibility
Consecutive patients with AML (n¼ 255) in their ﬁrst or second CR who
received HSCT from human leukocyte antigen (HLA)-mismatched familyTransplantation.
Table 1
Characteristics of Patients and Donors
Characteristics All Patients (n ¼ 255)
Age, y, median (range) of the recipient 26 (3-54)
0-20, No. (%) 87 (34)
21-40, No. (%) 130 (51)
41-54, No. (%) 38 (15)
Gender, No. (%)
Male 151 (59)
Female 104 (41)
FAB subtype, No. (%)
M0 6 (2)
M1 16 (6)
M2 110 (43)
M4 46 (18)
M5 65 (26)
M6 16 (4)
M7 1 (1)
WBC at diagnosis, 109/L, No. (%)
<20 165 (65)
20-49 27 (10)
50-99 35 (14)
100 28 (11)
Cytogenetics, NCCN criteria, No. (%)
Better risk 39 (15)
Intermediate risk 137 (54)
Poor risk 17 (7)
Unknown 62 (24)
Remission status, No. (%)
First complete remission (CR1) 228 (89)
Second complete remission (CR2) 27 (11)
Remission courses among CR1, No. (%)
CR after course 1 145 (64)
CR after course 2 66 (29)
CR after course 3 12 (5)
CR after course 4 5 (2)
Matched HLA locus
3 126
4 98
5 33
6 1
Donorerecipient gender
Maleemale 88
Maleefemale 55
Femaleemale 63
Femaleefemale 49
Donorerecipient blood type
Match 138
Minor mismatch 55
Major mismatch 49
Minor þ major 12
Donorerecipient relation
Fatherechild 67
Motherechild 61
Siblingesibling 96
Childeparent 19
Other 12
Age, y, median (range) of the donor 40 (13-63)
Comorbidity score*
0 186
1 30
2 39
CMV serostatus
Recipient and donor 5
Recipient or donorþ 250
Median CD34þ count, 106/kg (range) 2.2 (0.3-55.3)
Median CD3 þ count, 108/kg (range) 1.5 (0.2-8.3)
* Comorbidity score was according to published criteria [33].
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Forty-ﬁve of the 255 AML patients were previously enrolled in a study in
2009 [12]. These patients previously reported were enrolled and followed
further in this study. All protocols were approved by the institutional review
board of the Peking University Institute of Hematology, and all patients and
their donors signed consent forms.
One hundred ninety-three patients (75%) had diagnostic cytogenetic
results. These patients were classiﬁed into 3 groups, according to the
National Comprehensive Cancer Network (NCCN) criteria [13]: better risk
(n ¼ 39), intermediate risk (n ¼ 137), and poor risk (n ¼ 17). The reasons for
the patients being transplanted with better-risk cytogenetics were as
follows: t (8;21) with complex karyotypes or del(9q), according to South-
west Oncology Group/Eastern Cooperative Oncology Group (SWOG/ECOG)
criteria [14] (n ¼ 7); not achieving CR after two courses of chemotherapy
(n ¼ 5); CR2 at the time of transplantation (n ¼ 5); AML1/ETO or CBFb/
MYH11 transcript level greater than 103 at the time of transplantation
(n ¼ 10); and transplanted before 2007 (n ¼ 12). The patients were not
evaluated for recently described molecular prognostic factors, such as the
Flt3 internal tandem duplication, the NPM1 mutation, and the c-Kit muta-
tion, until 2009, so this information is not provided in the present study.
All donorerecipient pairs were typed at the HLA-A, -B, and -DR loci.
HLA-A and HLA-B typing was performed by intermediate-resolution DNA
typing, whereas HLA-DRB1 typing was performed using high-resolution
DNA techniques. For each donorerecipient pair, the patient received stem
cells from a family member who shared one HLA haplotype with the patient
but who differed to some degree in the HLA-A, -B, and -D antigens of the
haplotype that was not shared. In addition, HLA typing was performed on
the parents and offspring of each donorerecipient pair to guarantee a true
haploid genetic background among the pairs. HLA disparity and other
characteristics of the patients and donors are summarized in Table 1.
CONDITIONING REGIMEN
The conditioning therapy consisted of cytarabine
(4 g/m2/day) administered intravenously on days 10 to 9,
busulfan (4mg/kg/day) administered orally on days8 to6
(before January 2008), or busulfan (3.2 mg/kg/day) admin-
istered intravenously on days 8 to 6 (after January 2008),
cyclophosphamide (1.8 g/m2/day) administered intrave-
nously on days 5 to 4, Me-CCNU (250 mg/m2) adminis-
tered orally once on day 3, and, between 2003 and 2004,
ATG (either 20 mg/kg/day, porcine [Bioproduct, Wuhan,
China] in 5 patients or 2.5 mg/kg/day, rabbit [Sang Stat, Lyon,
France] for all other 250 patients) intravenously on days 5
to 2.
Graft-versus-Host Disease Prophylaxis
All transplantation recipients were administered cyclo-
sporine A (CsA), mycophenolate mofetil (MMF), and short-
term methotrexate. The dosage of CsA was 2.5 mg/kg/day
administered intravenously and was administered from day
9 before transplantation until bowel function returned to
normal. At that point, the patient was switched to oral CsA.
MMF was administered orally (0.5 g every 12 hours) from
day 9 before transplantation to day 30 after transplantation.
MMF was tapered from 1 g/day to 0.5 g/day on day 30 and
was discontinued on day 60. On day 1 after transplantation,
15 mg/m2 methotrexate was administered intravenously,
and on days 3, 6, and 11 after transplantation, 10 mg/m2
methotrexate was administered. The whole-blood CsA
concentration was monitored twice per week using ﬂuores-
cence polarization immunoassay, and the dosage was
adjusted to a blood concentration of 150 to 250 ng/mL. If
there was no evidence of graft-versus-host disease (GVHD at
days 90 to 100, the CsA dosage was gradually reduced and
was discontinued at approximately day 180. If GVHD was
observed, the CsA was continued.
Collection of Hematopoietic Cells
The donors were primed with recombinant human
granulocyte colony-stimulating factor (ﬁlgrastim, Kirin,Japan; 5 mg/kg/day) injected subcutaneously for 5 to 6
consecutive days. On the 4th day, bone marrow cells were
harvested. The target mononuclear cell count was 3  108
cells/kg of the recipient’s weight. On the 5th day (and on the
6th day, if necessary, ie, if the target mononuclear cell count
was not reached on the 5th day), peripheral blood stem cells
were collected with a COBE Blood Cell Separator (Spectra
Table 2
Causes of Death
Cause No. Patients (n ¼ 66)
Relapse 33
Graft-versus-host disease 3
Infections 29
Bacteria 7
Fungal 9
Viral 13
Organ failure 1
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from a total blood volume of 10 L. The protocol called for the
collection of at least 6  108 mononuclear cells/kg or 4  106
CD34þ cells/kg. The fresh and unmanipulated bone marrow
and PBSCs were infused into the recipient on the day of
collection. In instances of ABO major blood group incom-
patibility, the red cells were removed from the bone marrow
cells by density gradient sedimentation with Hespan (Braun,
Irvine, California) according to the manufacturer’s instruc-
tions. The surface markers of the cells in the grafts were
determined by 2- or 3-color staining using monoclonal
antibodies speciﬁc for CD34, CD3, CD4, and CD8 cells.
Prevention, Monitoring, Intervention, and Treatment of
Relapse
Starting in January 2006, minimal residual disease (MRD)
targets were regularly monitored after transplantation, and
starting in January 2009, MRD targets were also regularly
examined in the 2 weeks before the transplantation. The
bone marrow samples were deﬁned as abnormal if they
contained more than .001% of leukemia-associated aberrant
immune phenotypes [15] or more than 0.6% of Wilms tumor
gene 1 (WT1) [16]. MRD-positive status was deﬁned as either
two consecutive abnormalities in leukemia-associated
aberrant immune phenotypes or WT1 over a 2-week
interval or as an abnormality of both WT1 and leukemia-
associated aberrant immune phenotypes in a single bone
marrow sample. Starting in 2007, DLI or interleukin-2 was
given, according to donor availability, as an intervention
for MRD-positive status [17]. We made several modiﬁcations
to classic DLI, as previously described in detail [18].
When hematologic relapse was diagnosed after HSCT, the
relapse was treated with chemotherapy, followed by thera-
peutic DLI [19].
Deﬁnitions and Assessments
CR was deﬁned as morphologically normal marrow with
less than 5% blasts. Normal ﬁndings for peripheral blood
were required at the evaluation of the induction course.
Relapse was deﬁned as the presence of more than 20% blasts
in the bonemarrow or blasts at extramedullary sites. Positive
MRDwas deﬁned as noted above. The patients who hadMRD
were not classiﬁed as having relapsed. Cytogenetic classiﬁ-
cation was based on the NCCN criteria. The patients with
unknown, unperformed, or unsuccessful cytogenetics were
grouped together as an unknown group. In addition, the
classiﬁcations used by SWOG/ECOG, Medical Research
Council [20] and International System for Cytogenetic
Nomenclature [21] were also compared in terms of
leukemia-free survival (LFS). With regard to morphology, the
FAB cytological classiﬁcation was used. Assessments of
engraftment, chimerism, and GVHD and surveillance for
infection were previously described in detail [12].
Statistical Analyses
The cumulative incidences were estimated for engraft-
ment, GVHD, infection, relapse, TRM, MRD after trans-
plantation, and DLI intervention for positive MRD to
accommodate the competing risks. Relapse was a competing
risk for TRM, and TRMwas a competing risk for engraftment,
GVHD, infection, relapse, MRD after transplantation, and DLI
intervention for positive MRD. The associations among the
potential factors and outcomes were evaluated using an add-
on package for R statistical software (Bell Labs, New Jersey)
that allows for the estimation of a semiparametricproportional hazards model for the subdistribution of
competing risk analyses, as proposed by Scrucca et al [22].
The probabilities of overall survival (OS) and LFS were esti-
mated by the Kaplan-Meier method. Potential prognostic
factors were evaluated in univariate analyses by the log-rank
test, with P < .05 considered statistically signiﬁcant. In the
multivariate analysis, all factors found to inﬂuence the
outcomes in univariate analysis with a P < .15 were included
in a Cox proportional hazard model using time-dependent
variables. In these regression models, the occurrence of
acute and chronic GVHD was treated as a time-varying co-
variate. The potential interactions among the signiﬁcant
covariates were tested. No interactions were detected. SAS,
version 8.2 (SAS Institute, Cary, NC) and S Plus 2000 (Math-
soft, Seattle, WA) were used for most of the analyses. The
endpoint of the last follow-up for all surviving patients was
December 31, 2011.
RESULTS
Overall Outcome
For the entire study population, up to December 31, 2011,
181 patients were alive, with a median follow-up of 1,075
days (range, 365 to 3,398 days) after transplantationwithout
disease recurrence. The probabilities of OS and LFS were
72.9% (conﬁdence interval [CI], 67.1% to 78.7%) and 70.1% (CI,
64.3% to 75.9%) at 3 years, respectively. Thirty-three patients
died from causes other than relapse. The TRM rate at 2 years
was 13.1% (CI, 8.9% to 17.3%). Causes of death are shown in
Table 2.
Among patients with regular MRD monitoring after HSCT
(underwent transplantation after January 2006, n ¼ 236), 30
patients had positive MRD, among whom 18 patients
received DLI as an intervention for positive MRD. In total, 41
patients experienced leukemia relapses at a median time of
210 days (range, 30 to 730 days) after transplantation,
reaching a cumulative incidence of relapse of 16.8% (CI, 12.0%
to 21.6%) at 2 years. Thirty-three of the 41 cases of relapse
occurred within the ﬁrst year after transplantation. At the
time of the last follow-up, 33 patients had died after relapses,
with a median time to death of 330 days (range, 46 to 817)
after HSCT and 100 days (range, 0 to 456) after relapse.
Engraftment
Two-hundred ﬁfty-four patients (99.2%) achieved sus-
tained myeloid engraftment. Polymerase chain reaction DNA
ﬁngerprinting of short tandem repeats on recipient periph-
eral blood cells was used to conﬁrm 100% donor chimerism
in these patients. The median time to reach an absolute
neutrophil count above 0.5  109cells/L was 13 days (range,
10 to 23 days). The cumulative 30-day myeloid engraftment
probability was 99.1% (CI, 98.9% to 99.3%). The one patient
who failed myeloid engraftment died from heart failure on
day 13 post-HSCT. During the follow-up period, 240 patients
Table 3
Univariate Analysis of Transplantation Outcomes in 255 Patients Treated
With Haploidentical/Mismatched HSCT
Risk Factors Relapse (%) OS (%) LFS (%)
Cytogenetics (n ¼ 193)
Better risk 21 63 61
Intermediate risk 11 80 79
Poor risk 34 58 54
P value .047 .051 .035
Response to induction therapy and
remission status
CR1, CR after course 1 or 2 12 80 75
CR1, CR after course 3 or 4 53 49 47
CR2 30 56 54
P value .001 .031 .023
WBC count at diagnosis, 109/L
<50 12 78 76
50 22 69 64
P value .064 .183 .085
FAB subtype
M2 13 7 78
Other than M2 18 71 65
P value .42 .426 .087
MRD before transplantation (n ¼ 130)
Negative 10 78 76
Positive 35 57 52
P value .002 .397 .041
Matched HLA locus
3 15 73 70
4 17 72 66
5 18 91 81
P value .966 .119 .235
Donorerecipient gender
Maleemale 16 75 75
Maleefemale 20 75 69
Femaleemale 11 69 68
Femaleefemale 18 71 67
P value .693 .658 .741
Donorerecipient blood type
Match 17 71 69
Minor mismatch 13 77 75
Major mismatch 16 70 67
Minor þ major 17 78 69
P value .815 .694 .665
Donorerecipient relation
Fatherechild 15 78 75
Motherechild 18 63 62
Siblingesibling 14 78 76
Childeparent 21 67 62
Other 25 66 50
P value .692 .182 .092
Age of the donor
40 y 16 77 72
>40 y 17 71 70
P value .781 .486 .573
Comorbidity score*
0 18 69 66
1 22 54 54
2 16 71 71
P value .800 .394 .538
CD34þ count
Less than median 15 72 70
At least median 18 72 70
P value .621 .859 .921
CD3þ count
Less than median 16 75 74
At least median 18 70 69
P value .681 .702 .476
Absolute lymphocyte count at
day 30*
<300/mL 13 59 58
300/mL 17 81 75
P value .767 .001 .008
* Absolute lymphocyte count at day 30 was chosen as representative of
lymphocyte recovery based on our previously published literature [34].
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to reach a platelet count above 20  109cells/L was 16 days
(range, 7 to 195 days).
GVHD
At 100 days after transplantation, the cumulative inci-
dence was 39.5% (CI, 33.3% to 45.2%) for grade 2 to 4 acute
GVHD and 11.1% (CI, 9.1% to 13.1%) for grade 3 to 4 acute
GVHD. The cumulative incidence was 53.4% (CI, 46.4% to
60.4%) for total chronic GVHD and 19.9% (CI, 14.5% to 25.3%)
for extensive chronic GVHD at 2 years after transplantation.
Treating the occurrence of GVHD as a time-varying covariate,
the occurrence of grade 2 to 4 acute GVHD did not affect
relapse (P ¼ .463), LFS (P ¼ .935), or OS (P ¼ .954), whereas
the occurrence of grade 3 to 4 acute GVHD did not affect
relapse (P ¼ .743) but did lower LFS (P ¼ .016) and OS
(P ¼ .001) by increasing TRM (P ¼ .001). The occurrence of
chronic GVHD did not affect relapse (P ¼ .380), LFS (P¼ .327),
or OS (P¼ .103), whereas the occurrence of extensive chronic
GVHD did not affect relapse (P ¼ 0.977) but did lower LFS
(P ¼ .001) and OS (P ¼ .037) by increasing TRM (P ¼ .006).
Infection Complication
The 1-year cumulative incidence of cytomegalovirus
(CMV) antigenemia, Epstein-Barr virus reactivation,
varicella-zoster virus infection, and fungi infection was
61.2%, 11.5%, 7.2%, and 7.1%, respectively. CMV antigenemia
occurred in 17 of 34 patients (50.0%) with HLA mismatch at
0-1 locus, 51 of 95 patients (53.7%) with mismatch at 2 loci,
and 88 of 126 patients (69.8%) with mismatch at 3 loci
(P ¼ .018). The incidence of Epstein-Barr virus, varicella-
zoster virus, or fungi infection was not associated with the
extent of HLA disparity.
Cytogenetics
For patients with known cytogenetics, univariate analysis
of outcomes is shown in Table 3. According to published
criteria with regard to monosomal karyotype [23], LFS was
lower in patients with monosomal karyotype (n ¼ 15, 47%)
than in patients without monosomal karyotype (n ¼ 178,
75%) (P ¼ .153), although it did not reach statistical signiﬁ-
cance. Only 4 and 5 patients ﬁt in favorable and adverse
groups according to the recently published Center for Inter-
national Blood and Marrow Transplant criteria [24], so
patients were not reclassiﬁed. For patients with unknown
cytogenetics (n¼ 62), OS and LFS at 3 years was 64% and 59%,
respectively, and the cumulative incidence of relapse at
2 years was 21%.
Response to Induction Therapy
Response to induction therapy is shown in Table 3. For
patients achieving CR1 after induction therapy course 1, 2,
more than 2, or CR2, LFS at 3 years was 76%, 70%, 47%, and
54%, respectively (P ¼ .042); the cumulative incidence of
relapse at 2 years was 9%, 18%, 53%, and 30%, respectively
(P ¼ .001). LFS was 76% and 65% for patients achieving or not
achieving CR after course 1 (P ¼ .11), whereas LFS was 75%
and 47%, respectively, for patients achieving or not achieving
CR after 2 courses of therapy (P ¼ .027). Therefore, not
achieving CR after 2 courses of therapy was deﬁned as
difﬁculty achieving CR and was used as a variable in sub-
sequent analyses due to its more prominent differentiation.
Univariate analysis of outcomes is shown in Table 3.
Table 4
Multivariate Analyses of Relapse, LFS, and OS
Outcome Hazard Ratio
(95% CI)
P Value
Relapse
Response and remission status
CR1, CR after course 1 or 2 .26 (.12-.58) .001
CR1, CR after course 3 or 4 or CR2 1.0
LFS
Response and remission status
CR1, CR after course 1 or 2 .35 (.13-.89) .028
CR1, CR after course 3 or 4 or CR2 1.0
Extensive chronic GVHD versus no 3.62 (1.30-1.12) .014
Absolute lymphocyte count at day 30
<300/mL 2.16 (.93-5.02) .073
300/mL 1.0
OS
Response and remission status
CR1, CR after course 1 or 2 .33 (.13-.87) .024
CR1, CR after course 3 or 4 or CR2 1.0
Extensive chronic GVHD versus no 4.44 (1.61-12.19) .004
Absolute lymphocyte count at day 30
<300/mL 2.95 (1.20-7.22) .018
300/mL 1.0
Table 5
Risk Group Deﬁnitions
Risk Group Deﬁnition No. (%)
Low risk Patients with better-risk cytogenetics and
WBC count < 50  109/L, or patients with
better- or intermediate-risk cytogenetics
and in CR1, CR after course 1 or 2
145 (75)
High risk Patients with poor-risk cytogenetics, or
not in CR1, CR after course 1 or 2 (regardless
of cytogenetics), or with better-risk
cytogenetics and WBC count  50  109/L
48 (25)
Figure 1. Probability of LFS with respect to risk group after haploidentical
HSCT.
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Among the patients with known cytogenetics, 147
patients had initial WBC counts greater than 50  109/L, and
the other 46 patients had initial WBC counts less than
50  109/L. For these 2 groups, univariate analysis of
outcomes is shown in Table 3. Among the patients with
better-risk cytogenetics, LFS for patients with initial WBC
counts greater than 50  109/L and patients with initial WBC
counts less than 50  109/L were 33% versus 69% (P ¼ .033);
among patients with intermediate-risk cytogenetics, the
differences between the 2 groups were not signiﬁcant.
FAB Subtype
The most frequent FAB subtype was M2 (n ¼ 110). For
patients with an FAB subtype of M2 and for patients with an
FAB subtype other than M2, univariate analysis of outcomes
is shown in Table 3.
Univariate Analysis of Other Factors
Univariate analysis of transplantation-related character-
istics other than pretransplantation characteristics, including
HLA matching, donorepatient relationship, sex matching,
age of the donor, ABO compatibility, CD34 and T cell infused,
lymphocyte recovery, and comorbidity are shown in Table 3.
CMV serostatus was not considered as a covariate because
only 5 patients were low risk (recipient [R]e, donor [D]e) for
CMV reactivity (Table 1).
Multivariate Analyses
Among patients with known cytogenetics, not achieving
CR after 2 courses of therapy was the only signiﬁcant prog-
nostic factor for relapse, OS, and LFS (Table 4). There was
a trend toward LFS with regard to NCCN subgroup (P ¼ .093)
andWBC count (P¼ .086), although it did not reach statistical
signiﬁcance.
Risk Groups
A risk group classiﬁcation was generated according to
cytogenetics, not achieving CR after 2 courses of therapy and
initial WBC count (Table 5). The small number of patients
with poor-risk cytogenetics unavoidably resulted in less
statistical power, so in the ﬁnal risk system, the inclusion ofresponse to induction therapy allowed for tripling of the size
of the poor-risk group from 9% of the patients to 25%, and the
P value was thus more prominent.
Patients were classiﬁed as low or high risk. For these 2
groups, LFS at 3 years was 80% and 52%, respectively
(P ¼ .004, Figure 1); the cumulative incidence of relapse at 2
years was 8% and 36%, respectively (P ¼ .001, Figure 2). The
cumulative incidence of non-relapse mortality at 3 years was
11% and 10%, respectively (P¼ .95); the cumulative incidence
of positive MRD at 2 years was 7%, and 37%, respectively
(P ¼ .001); and the cumulative incidence of DLI intervention
for positive MRD at 2 years was 5% and 25%, respectively
(P ¼ .001).Comparative Cytogenetic Grouping
Although the outcomes analyzed by NCCN and the other
leukemia research groups were slightly different, the esti-
mated hazard ratios for the intermediate- versus poor-risk
group pointed in the same direction (Table 6). Based on the
risk group classiﬁcation described in “Risk Groups” above,
LFS for low-risk and high-risk patients was almost the same
(80% vs 52%, 81% vs 53%, 81% vs 49%, and 81% vs 49%,
respectively) according to the NCCN, SWOG/ECOG, Medical
Research Council, and International System for Cytogenetic
Nomenclature cytogenetic criteria systems.Outcomes in Different Age Groups
For adult patients (>20 years old) and children (20 years
old), LFS at 3 years was 71% and 68%, respectively (P ¼ .694).
Figure 2. Cumulative incidence of relapse characterized by risk group after
haploidentical HSCT.
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Groups” previously mentioned, LFS for low-risk and high-
risk adult patients and children was 80% versus 57%
(P ¼ .032) and 81% versus 47% (P ¼ .013), respectively.
MRD at Time of Transplantation
Among the patients with MRD examinations during the 2
weeks before transplantation (underwent transplantation
after January 2009, n ¼ 130), 110 patients had negative MRD,
and 20 patients had positive MRD before transplantation. For
these 2 groups, LFS at 3 years was 76% and 52%, respectively
(P¼ .041); the cumulative incidence of relapse at 2 years was
10% and 35%, respectively (P ¼ .002).
DISCUSSION
Allo-HSCT is currently recommended as the preferred
treatment choice for AML patients in CR1 without favorable
cytogenetics. Whether the risk factors currently recognized
in AML have any inﬂuence on transplantation outcomes in
this cohort of patients is uncertain. In the current report,
among all factors investigated, response after induction
therapy was the strongest predictor. By combining theTable 6
LFS Analysis According to Different Cytogenetic Grouping Systems
Grouping System No. LFS P Value
NCCN
Better risk 39 61 .035
Intermediate risk 137 79
Poor risk 17 54
SWOG .051
Favorable 32 61
Intermediate, other 119, 18 78, 82
Unfavorable 24 58
Medical Research Council
Favorable 39 61 .035
Intermediate 144 78
Adverse 10 56
International System for Cytogenetic
Nomenclature
.035
Good 39 61
Intermediate, bad 115, 26 79, 79
Very bad 13 51identiﬁed risk factors, we divided the entire study pop-
ulation into low- and high-risk groups with a survival
differential between the two groups of 30%.
In the current study cytogenetics, response after induc-
tion therapy, and WBC count in the better-risk cytogenetic
group were predictors of outcome in univariate analysis. The
results were in accordance with the observations of previous
reports [25,26]. The relapse rate of 53% for patients not
achieving CR after 2 courses was similar to that of advanced-
stage patients reported earlier [4,5]. The results suggested
that identiﬁcation of this group among other patients
undergoing transplantation during CR is very important and
that this group requires closer monitoring and more robust
therapy after HSCT. Despite the fact that outcomes are
superior among patients with good- or intermediate-risk
cytogenetics compared with patients with poor-risk cyto-
genetics, LFS for patients with unfavorable cytogenetics
appeared to be signiﬁcantly better than that achieved both
with chemotherapy or auto-HSCT [1,25,26] and with allo-
HSCT [9,23,24] in most published reports. It should be
acknowledged that the relatively small number of patients in
poor-risk cytogenetic groups might inﬂuence the results.
When using different classiﬁcations of cytogenetic groups,
the results showed the same trend, despite a slight difference
between the NCCN criteria and the other 3 leukemia cyto-
genetic classiﬁcation criteria. Patients with better-risk cyto-
genetics were selected as candidates for transplantations
when AML1/ETO or CBFb/MYH11 transcript levels were
greater than 103 at the time of the transplantation on the
basis of published data [27] and our own unpublished data
(Z.-H.H., manuscript in preparation). Apart from cytoge-
netics, the possible inﬂuence of recently described molecular
prognostic factors was not taken into account because data
on these factors were not routinely available with long-term
follow-up, but they will be the subject of future studies. The
effect of WBC count was more prominent in the better-risk
cytogenetic group. The ﬁndings were in agreement with
those of other studies [25,28]. Our results revealed that
AML1/ETO or CBFb/MYH11 transcript levels greater than
103 at the time of transplantation were correlated with
a higher WBC count (data not shown). This ﬁnding could
explain the outcome differences with regard to WBC count
among better-risk patients.
For patients classiﬁed as high risk by our risk stratiﬁcation
who underwent transplantation during CR, our result of
a 36% relapse rate was similar to or less than that reported in
patients with similar risks [2,9-11]. However, the TRM rate
was only 10%, which is much lower than the approximately
30% incidence for patients with similar risks reported by
other researchers [2,9,11] and for advanced-stage patients
reported by our group [18]. Better performance status,
compared with advanced-stage AML, and younger age,
compared with patients with similar risks reported by other
researchers, might have contributed to the lower non-
relapse mortality. Infection-related death accounted for 88%
of TRM. Regarding the impact of HLA and ATG dose on
infection, we found that a higher degree of HLA disparity was
associated with higher CMV incidence, which was in accor-
dancewith the report byMeyers et al. [29]. The development
of extensive chronic GVHD and grade 3 to 4 acute GVHD was
associated with higher risk for treatment-related mortality,
which was in agreement with the results of Kanda et al. [30].
Consequently, a similar relapse rate and lower TRM resulted
in a higher LFS of 52% compared with patients with similar
risks reported by other researchers and with advanced-stage
Y. Wang et al. / Biol Blood Marrow Transplant 19 (2013) 283e290 289patients reported by our group, for whom the LFS was re-
ported to be 17% to 38% [2,9,11,18].
Similar risk stratiﬁcation has not been fully studied or
universally recognized in allo-HSCT settings, perhaps due to
the heterogeneous regimens applied in matched-sibling
donor HSCT. In one study reporting on a subgroup analysis,
the P values were given as .006 and .07, respectively, with
regard to relapse and survival for matched-sibling HSCT
patients according to risk index [10]. Because the P value of
.07 was very close to statistical signiﬁcance, these results
revealed that such a risk identiﬁcation system might be
applicable in an allo-HSCT setting to stratify patients into
risk groups. Therefore, we initiated the current study to
stratify AML patients who underwent transplantation during
CR. We chose haploidentical patients as the study population
because the regimens (conditioning, GVHD prophylaxis,
stem cell source, and harvesting) were homogeneous. Our
results suggested that such a risk stratiﬁcation system might
be as applicable for patients undergoing allo-HSCT as it was
for patients in a chemotherapy setting. More intensive post
transplantation management might be developed for
patients with “high-risk” features to improve further the
overall outcomes of AML patients who underwent trans-
plantation during CR.
MRD examination has been found to be a strong predictor
of postremission chemotherapy and postautologous HSCT
[31,32]. Recently, we noted that MRD-directed DLI can
improve outcomes for patients who underwent trans-
plantation during CR [17]. In the subgroup analysis of the
current study, MRD pre-HSCT was a strong predictor of
outcomes post-HSCT. Due to the limited patient sample, our
results should be considered preliminary. The assessment of
MRD should be validated in future studies with larger pop-
ulations before and after allo-HSCT, andMRD perhaps should
be added into the risk evaluation system, in combination
with other factors, as a reliable and generally applicable
method for identifying patients at risk for relapse.
In conclusion, the pretransplantation risk factors inﬂu-
ence posttransplantation outcome of patients with AML in
CR after haploidentical HSCT and might be applicable to
assist with risk-directed posttransplantation therapy. Addi-
tional data are needed to validate in other transplantation
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